Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
VariZIG Market Value Growth And Long-Term Outlook
Historical growth was driven by factors including the accessibility of plasma fractionation techniques, a heightened understanding of varicella complications, the expansion of hospital-based preventative protocols, regulatory authorizations for hyperimmune globulins, and a robust immunization framework.
Expected market expansion during the forecast period is driven by the growing need to protect immunocompromised individuals, an increased focus on maternal and neonatal well-being, the expansion of plasma collection networks, advancements in screening for biologic safety, and rising investments in preventive immunotherapies. Concurrently, significant trends anticipated during this period include the wider application of passive immunization therapies, an enhanced focus on safeguarding high-risk patients, the diversification of plasma-derived biologic products, an increasing emphasis on prophylaxis after exposure, and improved practices for cold-chain management.
Get A Free Sample Report With In-Depth Market Insights:
VariZIG Market Development Factors: What’s Supporting Demand?
The varizig market is expected to be driven by the increasing incidence of varicella-zoster virus infections in the future. The varicella-zoster virus (VZV) is an extremely contagious virus that initially causes chickenpox and can later reactivate to manifest as shingles (herpes zoster). The rise in VZV infections, which result in conditions such as chickenpox and shingles, is linked to factors including reduced vaccination rates, an aging population, and immune suppression due to various medical therapies. varizig aids varicella-zoster virus patients by offering passive immunity, thus diminishing the severity and length of chickenpox symptoms, preventing complications in high-risk groups such as immunocompromised patients, and providing protection against severe outcomes for neonates and pregnant women exposed to the virus. For instance, in November 2024, data from the Florida Department of Health, a US-based government agency, indicated that varicella cases in 2023 climbed to 653, an increase from 428 cases recorded in 2022. Therefore, the growing incidence of varicella-zoster virus infections is a key factor propelling the varizig market.
VariZIG Market Segmentation And Category Overview
The varizig market covered in this report is segmented –
1) By Patient Condition: Immunocompromised Patients, Pregnant Women
2) By Distribution Channel: Hospitals, Pharmacies, Healthcare Providers
3) By End User: Adult, Geriatric, Pediatric
VariZIG Market Transformation Trends: What Innovations Are Driving Change?
Leading companies in the VariZIG market are prioritizing technological advancements, focusing on increasing manufacturing capacity and enhancing distribution logistics. This includes optimizing contract manufacturing, establishing regional supply-chain agreements, and improving cold-chain stability to ensure timely delivery of plasma-derived immunoglobulins to populations with high needs. Such manufacturing scale-up and distribution logistics encompass process and infrastructure innovations that boost production capacity, establish robust cold-chain and inventory management, facilitate regional supply agreements, and enable coordinated procurement contracts. These efforts transform specialized biologic products from limited availability into reliable, regionally accessible therapies. For instance, in January 2025, Kamada Ltd., an Israel-based biopharmaceutical company specializing in plasma-derived therapies, announced a $25 million three-year contract to supply KAMRAB and VARIZIG across Latin America from 2025 through 2027. This agreement secures regional supply and reduces the risk of shortages for at-risk patients, empowering hospitals and public health systems to plan prophylaxis and treatment with increased confidence. It also expands commercial access to a previously fragmented market by establishing predictable demand and distribution channels across multiple countries, supporting faster patient access. Finally, the contract bolsters public-health preparedness for varicella exposure in high-risk groups by guaranteeing an established supply pathway for an essential passive-immunity product.
VariZIG Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the varizig market are Emergent BioSolutions Inc.
View The Full VariZIG Market Report:
VariZIG Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the varizig market in 2025. The regions covered in the varizig market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
